跳至主要内容
临床试验/CTRI/2019/03/018331
CTRI/2019/03/018331进行中(未招募)未知

A pilot evaluation of prognostic molecularand serum biomarkers of disease recurrence after chemoradiation in patientswith locally advanced cervical cancer fromEMBRACE study group (BIOEMBRACE-1) - BIO-EMBRACE-1

Tata memorial Centre0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1) The study population will include patients recruited in the EMBRACE and EMBRACE-II studies that have completed treatment and have baseline and follow up information available.
  • 2) Tumour sample inclusion for the molecular study necessitates that at least >40% of the sample is composed of viable tumour cells.

排除标准

  • Tumour samples with less than < 40% viable tumour cells will be excluded

研究者

相似试验

招募中
2 期
Pilot study to evaluate the prognostic and metabolic effects of metformin during treatment of metastatic prostate cancer with androgen deprivation therapyMetastatic prostate cancerCancer - Prostate
ACTRN12614001054606Queensland University of Technology80
招募中
不适用
A pilot study to investigate prognostic marker of degeneration from cervical intraepithelial neoplasia to cervix carcinomaC53N87C51N90C52N89Malignant neoplasm of cervix uteriDysplasia of cervix uteriMalignant neoplasm of vulvaOther noninflammatory disorders of vulva and perineumMalignant neoplasm of vaginaOther noninflammatory disorders of vagina
DRKS00024987Carl von Ossietzky Universität/Klinikum Oldenburg; Universitätsklinik für Gynäkologie und Geburtshilfe550
已完成
2 期
An exploratory study to evaluate molecular predictive and/or prognostic factors of benefit from a randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer.nresectable advanced colorectal cancer
JPRN-UMIN000016165Department of clinical oncology, Kawasaki Medical School132
招募中
不适用
Prospective validation of the prognostic biomarker CD8+ TEMRA cells for disturbed fracture healing.S82.1S82.2S82.3S82.7S82.11S82.18S82.31S72S72.1S72.2S72.3S72.4S72.7S72.8Fracture of upper end of tibiaFracture of shaft of tibiaFracture of lower end of tibiaMultiple fractures of lower legFracture of femurPertrochanteric fractureSubtrochanteric fractureFracture of shaft of femurFracture of lower end of femurMultiple fractures of femurFractures of other parts of femur
DRKS00010872Charité Universitätsmedizin Berlin / Berlin-Brandenburger Centrum für Regenerative Therapien / Julius Wolff Institut800
已完成
不适用
Prospective study for predictive biomarkers and modified risk scoring model for venous thromboembolism in Japanese patients with unresectable or metastatic cancer.lung cancer, esophageal cancer, gastric cancer, biliary tract cancer, pancreatic cancer, colorectal cancer
JPRN-UMIN000026826Clinical Research Center, Saga University Hospital240